Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual MeetingGlobeNewsWire • 04/09/24
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsGlobeNewsWire • 04/04/24
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)Business Wire • 03/14/24
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual MeetingGlobeNewsWire • 03/05/24
Tempest Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/08/23
Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promiseMarket Watch • 10/11/23
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC StudyGlobeNewsWire • 10/11/23
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular CarcinomaGlobeNewsWire • 10/10/23
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and DevelopmentGlobeNewsWire • 09/19/23
All You Need to Know About Tempest Therapeutics, Inc. (TPST) Rating Upgrade to BuyZacks Investment Research • 08/15/23